Home › Funds › Frazier Life Sciences Management, L.P. › TARS

Frazier Life Sciences Management, L.P. position in TARS

TARSUS PHARMACEUTICALS INC · Health Care

Frazier Life Sciences Management, L.P. reported holding 728,644 shares of TARS (TARSUS PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$45.9M, representing 1.00% of its reported portfolio and ranking #22 among its reported holdings. Frazier Life Sciences Management, L.P. has disclosed TARS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)728.64K sh
Reported value held$45.86M
Portfolio Weight1.00%
First reportedQ3 2023
Last changeHold
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Frazier Life Sciences Management, L.P.'s TARS position evolved

Frazier Life Sciences Management, L.P. first disclosed a stake in TARS in Q3 2023 at 1,787,527 shares (US$31.8M). The position peaked in Q4 2024 at 1,587,527 shares, worth US$87.9M. Across 12 filings, Frazier Life Sciences Management, L.P. increased the stake 0 time(s), trimmed it 4 time(s) and left it unchanged 7 time(s). The most recent filing (Q2 2026) shows 728,644 shares valued at US$45.9M. Notable position changes include a 38% trim in Q4 2025 (shares fell 14% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 1.79M $31.76M New
Q4 2023 1.79M $36.20M Hold
Q1 2024 1.79M $64.98M Hold
Q2 2024 1.59M $43.15M Reduce
Q3 2024 1.59M $52.21M Hold
Q4 2024 1.59M $87.90M Hold
Q1 2025 1.40M $71.79M Reduce
Q2 2025 1.40M $56.61M Hold
Q3 2025 1.17M $69.39M Reduce
Q4 2025 728.64K $59.66M Reduce
Q1 2026 728.64K $51.11M Hold
Q2 2026 728.64K $45.86M Hold

Dots on the line are colored by change type; missing quarters mean no position was reported.

About TARS and 13F data

TARS (TARSUS PHARMACEUTICALS INC) is a Health Care company. 39 other funds we track also report a position in TARS — the largest reported positions include Deep Track Capital, LP (US$230.8M), RTW INVESTMENTS, LP (US$211.3M), Paradigm Biocapital Advisors LP (US$174.7M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding TARS

All TARS fund holders →

FAQ

How long has Frazier Life Sciences Management, L.P. held TARS?

Frazier Life Sciences Management, L.P. has disclosed TARS holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Frazier Life Sciences Management, L.P.'s current position in TARS?

As of Q2 2026, Frazier Life Sciences Management, L.P. holds 728.64K shares of TARS (TARSUS PHARMACEUTICALS INC), valued at $45.86M, representing 1.00% of its reported portfolio and ranking #22.

Has Frazier Life Sciences Management, L.P. been buying or selling TARS?

In the latest 13F filing (Q2 2026), Frazier Life Sciences Management, L.P. held unchanged its position in TARS. The position peaked in Q4 2024 at 1.59M shares.

Which other funds hold TARS?

Other major institutional holders of TARS include Deep Track Capital, LP, RTW INVESTMENTS, LP, Paradigm Biocapital Advisors LP, among 39 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.